MENU
Advertisement
Show Filters
Refine by Content Type
Refine by Year
Sort By:
Choose Sites to Search:
Applying Micropuncture Access
When and how this technique is useful in large-sheath procedures.
By Itsik Ben-Dor, MD; Nelson L. Bernardo, MD; Lowell F. Satler, MD; Augusto D. Pichard, MD; and Ron Waksman, MD
The Current Role of Bare-Metal Stents
An evaluation of the importance of BMS in contemporary practice.
By Itsik Ben-Dor, MD; Ron Waksman, MD; Augusto D. Pichard, MD; Joseph Lindsay, MD; and Lowell F. Satler, MD
Improvements in Femoral Access and Closure for TAVR
A focus on early recognition and prompt percutaneous endovascular management of failure of femoral artery percutaneous preclosure.
By Nelson L. Bernardo, MD, and Augusto D. Pichard, MD
Clinical and Imaging Requirements for TAVI
Transcatheter aortic valve implantation is an alternative treatment for patients with severe aortic stenosis who are at high surgical risk or are considered inoperable.
By Itsik Ben-Dor, MD; Gabriel Maluenda, MD; Ron Waksman, MD; Lowell F. Satler, MD; Gaby Weissman, MD; Nelson Puig; and Augusto D. Pichard, MD
Chief Medical Editor's Page
Optimal PCI in Contemporary Practice
By Ted E. Feldman, MD, FSCAI, Chief Medical Editor
Aortic and Mitral Valves
By Ted E. Feldman, MD, FSCAI
By Ted E. Feldman, MD, FESC, FACC, FSCAI
Bioresorbables Plus Access & Closure
By Ted E. Feldman, MD, MSCAI, FACC, FESC
Rouen Experience Supports Safety of TAVR Using Local Anesthesia
May 9, 2012—In an expedited publication online in the Journal of the American College of Cardiology: Cardiovascular Interventions, Eric Durand, MD, et al reported findings on the feasibility and 30-day outcomes of transcatheter aortic valve replacement (TAVR) with the Edwards Sapien and Edwards Sapien XT prostheses (Edwards Lifesciences, Irvine, CA) implanted exclusively using local anesthesia and fluoroscopic guidance.
What Is the utility of OCT in detecting an unsuspected calcified coronary lesion?
Sponsored by St. Jude Medical
By Gabriel Maluenda, MD, and Augusto Pichard, MD, FACC
FDA Panel Recommends Approval of Edwards Sapien Transcatheter Valve for Treatment of Inoperable Patients
July 20, 2011—Edwards Lifesciences (Irvine, CA) announced that a US Food and Drug Administration advisory panel voted to recommend approval of the Edwards Sapien transcatheter heart valve for the treatment of certain inoperable patients. Edwards submitted a premarket approval application in the fall of 2010 based on data from the inoperable cohort of the PARTNER trial. In the United States, the Edwards Sapien valve is an investigational device and is not yet commercially available.
Structural and Valvular Update
Proposed Legislation Seeks to Improve FDA Regulatory Process for Medical Devices
October 13, 2011—United States Senators Amy Klobuchar (D-MN), Richard Burr (R-NC), and Michael Bennet (D-CO) announced the introduction of legislation that seeks to help boost medical innovation by reducing regulatory burdens that unnecessarily delay beneficial new medical products from reaching patients.
OCT-Guided PCI: Lessons From the ILUMIEN IV: OPTIMAL PCI Trial
A discussion of study design, insights into the results, and the current and future role of OCT-guided stent implantation and optimization.
By Ziad A. Ali, MD, DPhil; Doosup Shin, MD; and Richard A. Shlofmitz, MD
Catheter-Based Renal Denervation
A review of the evidence for a novel treatment for hypertension.
By Anna K. Krawisz, MD, and Eric A. Secemsky, MD, MSc, RPVI, FACC, FSCAI, FSVM
